Biocon completes Rs. 4,150 crore equity fundraise through QIP
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Subscribe To Our Newsletter & Stay Updated